
Solid Biosciences rose 57.6% from $4.34 to $6.84, ahead of the S&P 500's +11.2%. Its worst day was Oct 13 (−13.3%), and its low came Nov 17 at $4.34.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.
+14.1% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Solid Biosciences shares rose 12.6%, while the S&P 500 fell 0.5%.
+12.6% · S&P 500 −0.5%
Solid Biosciences shares rose 20.3%, while the S&P 500 fell 1.3%.
+20.3%, the year's best day · S&P 500 −1.3%
EPS of $-0.53 missed the $-0.52 estimate on $0.00 revenue.
−1.3% · S&P 500 −1.4%
EPS of $-0.52 missed the $-0.43 estimate on $0.00 revenue.
−4.4% · S&P 500 +0.6%
Solid Biosciences shares rose 14.0%, while the S&P 500 rose 1.0%.
+14.0%, on 15M shares, the year's heaviest volume · S&P 500 +1.0%
Solid Biosciences closed at its highest level of the year, 156.9% above where the year started.
+0.7% · S&P 500 −0.5%
EPS of $-0.38 beat the $-0.46 estimate on $0.00 revenue.
−3.7% · S&P 500 +0.6%
Solid Biosciences shares fell 13.3%, while the S&P 500 fell 0.0%.
−13.3%, the year's worst day · S&P 500 0.0%
EPS of $-0.36 beat the $-0.40 estimate on $0.00 revenue.
−5.2% · S&P 500 −4.4%
Where it ended: a close of $6.84 on Nov 13, 2026.
Nothing in the past 12 months.
All SLDB dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SLDB and SPY from Benzinga historical bars. Not investment advice.